Do comorbidity influences acute toxicity and outcome in elderly patients with endometrial cancer treated by adjuvant radiotherapy plus brachytherapy?

A. Fiorentino, C. Chiumento, V. Fusco

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To correlate comorbidity and acute radiation toxicity in elderly patients treated with adjuvant external beam radiotherapy (EBRT) plus brachytherapy-high dose rate (HDR-BRT) for endometrial cancer (EC). Methods: Endometrial cancer patients over 65 were treated and evaluated for comorbidity assessment with ACE-27 and Charlson comorbidity index (CCI). EBRT total dose was 45-50.4 Gy (1.8 Gy/day). The vault vagina boost of dose was performed by HDR-BRT with 2/3 fractions with a total dose of 10-15 Gy. Results: From 2008 to 2011, 35 patients were analyzed. Eighteen patients (51.43 %) had not ACE-27 comorbidity; while 27 patients (77.14 %) had CCI lower than three. During treatment, acute toxicity was mild and not influenced by the comorbidity score. Two-year Progression Free and Overall Survival were 69 and 80 %. ACE-27 and CCI did not affect progression-free survival (p = 0.51, p = 0.3) and OS (p = 0.26, p = 0.5). Conclusion: External beam radiotherapy plus BRT-HDR are well tolerated in EC elderly with good performance status and low comorbidity profile.

Original languageEnglish
Pages (from-to)665-669
Number of pages5
JournalClinical and Translational Oncology
Volume15
Issue number8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Adjuvant Radiotherapy
Brachytherapy
Endometrial Neoplasms
Comorbidity
Radiotherapy
Disease-Free Survival
Vagina
Radiation

Keywords

  • Acute toxicity
  • Brachytherapy
  • Comorbidity
  • Endometrial cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

@article{03199270e38f4561b3f704f2f46abff8,
title = "Do comorbidity influences acute toxicity and outcome in elderly patients with endometrial cancer treated by adjuvant radiotherapy plus brachytherapy?",
abstract = "Purpose: To correlate comorbidity and acute radiation toxicity in elderly patients treated with adjuvant external beam radiotherapy (EBRT) plus brachytherapy-high dose rate (HDR-BRT) for endometrial cancer (EC). Methods: Endometrial cancer patients over 65 were treated and evaluated for comorbidity assessment with ACE-27 and Charlson comorbidity index (CCI). EBRT total dose was 45-50.4 Gy (1.8 Gy/day). The vault vagina boost of dose was performed by HDR-BRT with 2/3 fractions with a total dose of 10-15 Gy. Results: From 2008 to 2011, 35 patients were analyzed. Eighteen patients (51.43 {\%}) had not ACE-27 comorbidity; while 27 patients (77.14 {\%}) had CCI lower than three. During treatment, acute toxicity was mild and not influenced by the comorbidity score. Two-year Progression Free and Overall Survival were 69 and 80 {\%}. ACE-27 and CCI did not affect progression-free survival (p = 0.51, p = 0.3) and OS (p = 0.26, p = 0.5). Conclusion: External beam radiotherapy plus BRT-HDR are well tolerated in EC elderly with good performance status and low comorbidity profile.",
keywords = "Acute toxicity, Brachytherapy, Comorbidity, Endometrial cancer, Radiotherapy",
author = "A. Fiorentino and C. Chiumento and V. Fusco",
year = "2013",
month = "8",
doi = "10.1007/s12094-012-0986-9",
language = "English",
volume = "15",
pages = "665--669",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "8",

}

TY - JOUR

T1 - Do comorbidity influences acute toxicity and outcome in elderly patients with endometrial cancer treated by adjuvant radiotherapy plus brachytherapy?

AU - Fiorentino, A.

AU - Chiumento, C.

AU - Fusco, V.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: To correlate comorbidity and acute radiation toxicity in elderly patients treated with adjuvant external beam radiotherapy (EBRT) plus brachytherapy-high dose rate (HDR-BRT) for endometrial cancer (EC). Methods: Endometrial cancer patients over 65 were treated and evaluated for comorbidity assessment with ACE-27 and Charlson comorbidity index (CCI). EBRT total dose was 45-50.4 Gy (1.8 Gy/day). The vault vagina boost of dose was performed by HDR-BRT with 2/3 fractions with a total dose of 10-15 Gy. Results: From 2008 to 2011, 35 patients were analyzed. Eighteen patients (51.43 %) had not ACE-27 comorbidity; while 27 patients (77.14 %) had CCI lower than three. During treatment, acute toxicity was mild and not influenced by the comorbidity score. Two-year Progression Free and Overall Survival were 69 and 80 %. ACE-27 and CCI did not affect progression-free survival (p = 0.51, p = 0.3) and OS (p = 0.26, p = 0.5). Conclusion: External beam radiotherapy plus BRT-HDR are well tolerated in EC elderly with good performance status and low comorbidity profile.

AB - Purpose: To correlate comorbidity and acute radiation toxicity in elderly patients treated with adjuvant external beam radiotherapy (EBRT) plus brachytherapy-high dose rate (HDR-BRT) for endometrial cancer (EC). Methods: Endometrial cancer patients over 65 were treated and evaluated for comorbidity assessment with ACE-27 and Charlson comorbidity index (CCI). EBRT total dose was 45-50.4 Gy (1.8 Gy/day). The vault vagina boost of dose was performed by HDR-BRT with 2/3 fractions with a total dose of 10-15 Gy. Results: From 2008 to 2011, 35 patients were analyzed. Eighteen patients (51.43 %) had not ACE-27 comorbidity; while 27 patients (77.14 %) had CCI lower than three. During treatment, acute toxicity was mild and not influenced by the comorbidity score. Two-year Progression Free and Overall Survival were 69 and 80 %. ACE-27 and CCI did not affect progression-free survival (p = 0.51, p = 0.3) and OS (p = 0.26, p = 0.5). Conclusion: External beam radiotherapy plus BRT-HDR are well tolerated in EC elderly with good performance status and low comorbidity profile.

KW - Acute toxicity

KW - Brachytherapy

KW - Comorbidity

KW - Endometrial cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84880319368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880319368&partnerID=8YFLogxK

U2 - 10.1007/s12094-012-0986-9

DO - 10.1007/s12094-012-0986-9

M3 - Article

C2 - 23359175

AN - SCOPUS:84880319368

VL - 15

SP - 665

EP - 669

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 8

ER -